Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. 

We are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. We are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.

Janus Henderson Investors

Franklin Templeton

Access Biotechnology

Atlas Venture

Boxer Capital

Canaan Partners

T. Rowe Price

Viking Global Investors

Perceptive Advisors

RA Capital Management

Day One Biopharmaceuticals

Molly’s advice for others going through a pediatric low-grade glioma (#pLGG) journey is to keep a list of questions to ask the doctor — even the small things. To hear more stories from people living with pLGG and tips for navigating a challenging diagnosis, visit: https://lnkd.in/eDtwpMUz

#RethinkpLGG

Today, we celebrate and support raising awareness for #RareDiseaseDay! More than 300 million people around the world live with a rare disease. Though considered a rare #cancer, pediatric low-grade glioma (pLGG) accounts for approximately 30% of all childhood brain tumors. There is a considerable need for increased visibility and awareness for #pLGG and all rare diseases. 

Head of R&D and co-founder Samuel Blackman shares the Day One journey to reshape #pediatriccancer drug development in this article for the Pediatric Cancer Research Foundation’s Profectus blog, Turning “One Day” into “Day One”: https://bit.ly/3URbMzF

Our co-founder and Head of R&D, Samuel Blackman, recently sat down with Michael Pietrack of The Pharmaverse Podcast to discuss how Sam’s expedition to the base camp of Mount Everest influenced his #leadership philosophy. Sam speaks to the power of vulnerability and camaraderie and how these universal lessons can positively impact the compassionate care provided to young patients and their families. Watch the full episode here: https://lnkd.in/epZpSG3C 

Today, on #NationalCaregiversDay, we spotlight the selfless care, love and support #caregivers provide to those who need it most. Remember to thank a #caregiver, not only today, but every day, for helping our loved ones live better lives.

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-16.98M -	-43.84M 158.14%	-72.75M 65.94%	-142.18M 95.43%	-188.92M 32.87%
depreciation and amortization		155K -	199K 28.39%	531K 166.83%	383K 27.87%
deferred income tax					-2.32M -
stock based compensation	111K -	526K 373.87%	13.32M 2,432.51%	27.24M 104.50%	39.34M 44.41%
change in working capital	444K -	-357K 180.41%	2.69M 854.90%	6.56M 143.56%	9.42M 43.48%
accounts receivables
inventory
accounts payables	14K -	132K 842.86%	1.54M 1,068.18%	-1.48M 196.24%	2.32M 256.06%
other working capital	430K -	-489K 213.72%	1.15M 335.79%	8.05M 598.01%	-2.32M 128.78%
other non cash items	11.91M -	30.03M 152.06%	8M 73.36%	-2.03M 125.37%	-4.76M 134.58%
net cash provided by operating activities	-4.51M -	-13.49M 198.76%	-48.54M 259.84%	-109.87M 126.36%	-146.85M 33.66%
investments in property plant and equipment		-92K -	-8M 8,595.65%	-26K 99.67%	-3.22M 12,300%
acquisitions net				255.05K -	3M 1,076.25%
purchases of investments				-394.21M -	-443.84M 12.59%
sales maturities of investments				139.16M -	575.44M 313.52%
other investing activites				-255.05K -	-3M 1,076.25%
net cash used for investing activites		-92K -	-8M 8,595.65%	-255.07M 3,088.43%	128.38M 150.33%
debt repayment	-1M -
common stock issued	29.91M -	29.98M 0.24%	167.04M 457.24%	161.61M 3.25%	161.41M 0.12%
common stock repurchased			318K -	642K 101.89%	1.25M 94.70%
dividends paid
other financing activites	2M -	29.98K 98.50%	129.76M 432,755.19%	3.65M 97.19%	1.34M 63.33%
net cash used provided by financing activities	30.91M -	29.98M 3.00%	297.12M 891.16%	165.90M 44.16%	164.00M 1.15%
effect of forex changes on cash
net change in cash	26.39M -	16.40M 37.87%	240.58M 1,367.32%	-199.05M 182.74%	145.52M 173.11%
cash at beginning of period	942K -	27.33M 2,801.49%	43.73M 59.99%	284.31M 550.18%	85.26M 70.01%
cash at end of period	27.33M -	43.73M 59.99%	284.31M 550.18%	85.26M 70.01%	230.78M 170.68%
operating cash flow	-4.51M -	-13.49M 198.76%	-48.54M 259.84%	-109.87M 126.36%	-146.85M 33.66%
capital expenditure		-92K -	-8M 8,595.65%	-26K 99.67%	-3.22M 12,300%
free cash flow	-4.51M -	-13.58M 200.80%	-56.54M 316.31%	-109.90M 94.38%	-150.08M 36.56%

COM:DAYONEBIO

Day One Bio

Last Close

13.34

22/11 21:00

Market Cap

1.29B

Beta: -

Volume Today

591.56K

Avg: -

Preview